Publicacións nas que colabora con Luis Alfonso Gurpide Ayarra (23)

2020

  1. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

2019

  1. The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients

    Disease Markers, Vol. 2019

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2016

  1. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

2014

  1. Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging

  2. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

  3. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

  4. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Núm. 11, pp. 2058-2065

2012

  1. The multimodal management of locally advanced N2 non-small cell lung cancer: Is there a role for surgical resection? A single institution's experience

    Clinical and Translational Oncology, Vol. 14, Núm. 11, pp. 835-841

2010

  1. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

    Molecular Cancer, Vol. 9

2009

  1. EUELC project: A multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration

    European Respiratory Journal, Vol. 34, Núm. 6, pp. 1477-1486

  2. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

  3. Role of surgery in a multidisciplinary approach to superior sulcus tumors (SST): Morbidity and prognostic factors for long-term success after resection

    Thoracic and Cardiovascular Surgeon, Vol. 57, Núm. 6, pp. 353-357

2008

  1. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation

    Radiotherapy and Oncology, Vol. 88, Núm. 3, pp. 342-350

2007

  1. Carcinoma microcítico de pulmón

    Revista de medicina, Vol. 51, Núm. 2, pp. 7-13

  2. Nuevos tratamientos para el carcinoma renal

    Anales del sistema sanitario de Navarra, Vol. 30, Núm. 3, pp. 393-403

  3. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

  4. Small-cell lung cancer

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 2, pp. 7-13

2005

  1. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

    Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140

  2. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532